Viva Biotech is leveraging NVIDIA technology to enhance its AI-driven drug discovery process, particularly in designing mini-binders targeting the ActRIIA receptor, which is essential for addressing muscle wasting and lean mass issues.
The collaboration emphasizes Viva Biotech's innovative "Lab-in-the-Loop" methodology, which integrates computational design with high-throughput protein production and biophysical testing. This approach demonstrates how in silico predictions can be validated through real-world experiments, thereby accelerating the drug discovery timeline. By utilizing NVIDIA's BioNeMo alongside its own AI-driven platform, Viva Biotech is optimizing drug candidates more efficiently than traditional methods.
Through this initiative, the company is refining its Proteina-Complexa model to enhance sequence selection, resulting in more precise mini-binder designs. This AI-guided exploration of chemical spaces has led to improved design specificity and reduced costs and time in drug candidate nomination processes. As a prominent contract research organization, Viva Biotech aims to continue advancing its AI algorithms and drug discovery capabilities, reinforcing its position in the evolving landscape of AI-driven therapeutics.
This strategic partnership not only highlights the potential of AI in drug development but also sets a precedent for future collaborations between technology and life sciences, promising faster and more effective therapeutic solutions.